Sumanta Pal, Professor and Vice Chair of Academic Affairs at City of Hope, shared a post by Atul Batra, Medical Oncologist and Clinical Researcher at All India Institute of Medical Sciences, adding:
“Finally having a chance to review some of the most impactful presentations from ESMO25 outside of the GU space. Strongly encourage all to take a look at this critical dataset from Atul Batra, AIIMS, New Delhi.
- Single institution RP2 IST enrolled 160 pts over just 1 year (wow)
- Study compared neoadjuvant ddAC>T in stage II/II breast cancer +/- 1/10th the conventional dose of pembrolizumab
- Primary EP of improved pCR met
- Abs diff in pCR of 13.3% akin to that seen in KN522 (14.5%)
Tremendous results and may help improve access. My colleague Regina Barragan-Carrillo attempting to advance a study of low-dose nivolumab in kidney cancer in Latin America.”
Quoting Atul Batra’s post:
“Missed being home for Diwali this year, but had the honour of presenting the PLANET trial results from the ESMO podium — a moment that could light many more diyas across the Planet.
Happy Diwali to all.”
More posts featuring Sumanta Pal.
